

 <b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number:	Application Number:
	11669.139USC1	10/692,299
	Applicant: Ferrara et al.	
	Filing Date: October 22, 2003	Group Art Unit: 1644

## **FOREIGN PATENT DOCUMENTS**

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
↓ PnK	WO 99/06550	11.02.99	PCT	—	—	YES
↓	WO 99/63088	09.12.99	PCT	—	—	
	WO 00/52022	08.09.00	PCT	—	—	
	WO 00/53753	14.09.00	PCT	—	—	
	WO 00/70049	23.11.00	PCT	—	—	
	WO 00/73454	07.12.00	PCT	—	—	
	WO 00/75327	14.12.00	PCT	—	—	
↓	WO 01/36465	25.05.01	PCT	—	—	
↓	WO 01/40466	07.06.01	PCT	—	—	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

<i>PNT</i>	Aird, W.C. et al., 1997, <i>J. Cell Biol.</i> 138:1117-1124 "Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment"
<i>PNT</i>	Aravind, L. and Koonin, E.V., 1998, <i>Curr. Biol.</i> 8:477-478 "A cathepsin fold in the carboxy-terminal domain of the Wnt antagonists- the Dickkopfs"

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

 <b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)		Docket Number: 11669.139USC1	Application Number: 10/692,299
		Applicant: Ferrara et al.	
		Filing Date: October 22, 2003	Group Art Unit: 1644

<i>Pink</i>		Arbiser, J.L. et al., 1997, <i>Proc. Natl. Acad. Sci. USA</i> , 94:861-866 "Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways"
		Attwood et al., Oct 2000, <i>Science</i> 290(5491): 417-473 "The babel of bioinformatics"
		Basset, D.L., 1943, <i>Am. J. Anat.</i> , 73:251-278 "The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle"
		Boisbouvier, J. et al., 1998, <i>J. Mol. Biol.</i> 283: 205-219 "A structural homologue of colipase in black mamba venom revealed by NMR floating disulphide bridge analysis"
		Carmeliet, P., 2000, <i>Nature Medicine</i> , 6:389-395 "Mechanisms of angiogenesis and arteriogenesis"
		Collin, O. & Bergh A., 1996, <i>Int. J. Androl.</i> , 19:221-228 "Leydig cells secrete factors which increase vascular permeability and endothelial cell proliferation"
		Dellian, M. et al., 1996, <i>Am. J. Pathology</i> , 149:59-71 "Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment"
		Esser, S. et al., 1998, <i>J. Cell. Biol.</i> , 140:947-959 "Vascular endothelial growth factor induces endothelial fenestrations in vitro" (1998)
		Ferrara, N. & Alitalo, 1999, <i>Nature Medicine</i> , 5:1359-1364 "K. Clinical applications of angiogenic growth factors and their inhibitors"
		Ferrara, N. et al., 1998, <i>Nature Medicine</i> , 4:336-340 "Vascular endothelial growth factor is essential for corpus luteum angiogenesis"
		Ferrara, N., 2000, <i>Curr. Opin. Biotech</i> 11: 617-624 "VEGF: an update on biological and therapeutic aspects"
		Fogarty et al., 2002, <i>The Scientist</i> , 16(16):33
		Fraser et al., 2000, <i>Endocrinology</i> , 141(3):995-1000 "Suppression of Luteal Angiogenesis in the Primate after Neutralization of Vascular Endothelial Growth Factor"
		Gille, H. et al., 2001, <i>J. Biol. Chem.</i> , 276:3222-3230 "Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants"
		Glinka, A. et al., 1998, <i>Nature</i> , 391:357-362 "Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction"
<i>✓</i>		Goldzimer, J.W. & Green, J.A., 1962, <i>J. Clin. Endocrinol. Meta.</i> 22:325-332 "The polycystic ovary. I. Clinical and histologic features"

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	<i>9/26/05</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

<b>FORM 1449*</b> <i>P F</i> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)		Docket Number: 11669.139USCI	Application Number: 10/692,299
		Applicant: Ferrara et al.	
		Filing Date: October 22, 2003	Group Art Unit: <i>1644</i>

*MAY 6 2004*  
*J.C. A.*  
*PATENT & TRADEMARK OFFICE*

<i>R.A.K.</i>	Gospodarowicz et al., 1984, <i>J. Cell. Biol.</i> , 99:947-961 "Comparison of the Ability of Basement Membranes Produced by Corneal Endothelial and Mouse-derived Endodermal PF-HR-9 Cells to Support the Proliferation and Differentiation of Bovine Kidney Tubule Epithelial Cells in Vitro"
	Joubert, F.J. & Strydom, D.J., 1980, <i>Hoppe-Seylers Zeitschrift fur Physiologische Chemie</i> , 361:1787-1794 "Snake venom. The amino acid sequence of protein A from <i>Dendroaspis polylepis polylepis</i> (black mamba) veno"
	Klagsburn, M., 1992, <i>Semin. Cancer Biol.</i> , 3:81-87 "Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions"
	Krupnik, V.E. et al., 1999, <i>Gene</i> , 238:301-313 "Functional and structural diversity of the human Dickkopf gene family"
	LeCouter, J. et al., 2001, <i>Nature</i> , 412(6850):877-884 "Identification of an angiogenic mitogen selective for endocrine gland endothelium"
	Leung et al., 1989, <i>Science</i> , 246:1306-1309 "Vascular endothelial growth factor is a secreted angiogenic mitogen"
	Lind et al., 1995, <i>APMIS</i> , 103:140-146 "Chemotaxis of human osteoblasts"
	Melton, D. A. et al., 1984, <i>Nucleic Acids Res.</i> , 12:7035-7056 "Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter"
	Mesiano et al., 1993, <i>J. Clin. Endocrinol. Metab.</i> 76:968-976 "Mitogenic Action, Regulation, and Localization of Insulin-Like Growth Factors in the Human Fetal Adrenal Gland"
	Mueller et al., 1995, <i>Eur. J. Immunol.</i> , 25:1744-1746 "Cloning of ATAC, an activation-induced chemokine-related molecule exclusively expressed in CD7+ T lymphocytes"
	Ngo et al., in <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , 1994, Merz et al., (ed.), Birkhauser, Boston, MA, 443 and 492-495
	Palade, G.E. et al., 1979, <i>Acta Physiol. Scand. Suppl.</i> , 463:11-32 "Structural aspects of the permeability of the microvascular endothelium"
	Petterson, A. et al., 2000, <i>Lab. Invest.</i> 80:99-115 "Heterogeneity of the angiogenic response induced in different normal tissues by vascular permeability factor/vascular endothelial growth factor"
	Phillips, H.S. et al., 1990, <i>Science</i> 250:290-294 "Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons"
<i>✓</i>	Phillips et al., 1990, <i>Endocrinology</i> , 127:965-967 "Vascular endothelial growth factor is expressed in rat corpus luteum"

EXAMINER	<i>M.W. Yer</i>	DATE CONSIDERED	<i>9/26/03</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			



INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		Docket Number: 11669.139USC1	Application Number: 10/692,299
		Applicant: Ferrara et al.	
		Filing Date: October 22, 2003	Group Art Unit: 1644

PJK		Ravindranath et al., 1992, <i>Endocrinology</i> , 131(1):254-260 "Vascular Endothelial Growth Factor Messenger Ribonucleic Acid Expression in the Primate Ovary"
		Roberts and Palade, 1997, <i>Cancer Res.</i> , 57:765-772 "Host Microvasculature Influence on Tumor Vascular Morphology and Endothelial Gene Expression"
		Ryan A.M. et al., 1999, <i>Toxicol. Pathol.</i> 27:78-86 "Preclinical safety evaluation of rhuMAbVEGF, an Antiangiogenic humanized monoclonal antibody"
		Schweitz et al., 1999, <i>FEBS Lett.</i> 461:183-188 "MIT(1), a black mamba toxin with a new and highly potent activity on intestinal contraction"
		Semenza, G.L., 2000, <i>J. Appl. Physiol.</i> 88:1474-1480 "HIF-1: mediator of physiological and pathophysiological response to hypoxia"
		Simionescu, N. & Simionescu, M., 1988, ed. Weiss, L., Urban & Schwarzenberg, Baltimore 355-398 "The Cardiovascular System"
		Soker et al., 1998, <i>Cell</i> 92:735-745 "Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor"
		Skolnick et al., Jan 2000, <i>Trends in Biotech.</i> 18(1):34-39 "From genes to protein structure and function: novel applications of computational approaches in the genomic era"
		Stewart and Wiley, 1981, <i>Dev. Biol.</i> 84:183-192 "Developing Nervous Tissue Induces Formation of Blood-Brain Barrier Characteristics in invading Endothelial Cells: A Study Using Quail-Chick Transplantation Chimeras"
		Taub et al., 1995, <i>J. Clin. Invest.</i> 95:1370-1376 "T Lymphocyte Recruitment by Interleukin-8 (IL-8)"
		Van Tilburgh et al., 1992, <i>Nature</i> , 359:159-162 "Structure of the pancreatic lipase-procolipase complex"
		Wechselberger, C. et al., 1999, <i>FEBS Lett.</i> 462:177-181 "The mammalian homologues of frog Bv8 are mainly expressed in spermatocytes"
✓		Zetter, B.R., 1980, <i>Nature</i> , 285:41-43 "Migration of capillary endothelial cells is stimulated by tumour-derived factors"

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

Date Mailed: Nov. 4, 2004

Sheet 1 of 1

FORM 1449* <b>INFORMATION DISCLOSURE STATEMENT</b> IN AN APPLICATION (Use several sheets if necessary)			Docket Number: 11669.139USCI	Application Number: 10/692,299
			Applicant: FERRARA ET AL.	
			Filing Date: 10/22/2003	Group Art Unit: 1653 <u>1644</u>

*NOV 6 8 2004*

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PJK	4,946,778	08/1990	Ladner et al.			
1	5,858,682	01/1999	Gruenwald et al.			
	6,132,729	10/2000	Thorpe et al.			
/	6,180,370	01/2001	Queen et al.			
✓	6,485,938	11/2002	Sheppard et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PJK	Abaza et al., J. Protein Chemistry, Vol. 11, No. 5, pp. 433-444 (1992).
1	Brekken et al., Cancer Research, Vol. 58, No. 9, pp. 1952-59 (May 1998)
	Harlow et al., Antibodies - A Laboratory Manual, Cold Spring Harbor laboratory production, Cold Spring Harbor, NY, pp. 626-629 (1988)
	Kuby et al., Immunology, second edition, pgs. 85-96 (1994).
	Mikayama et al., Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor, Pro. Natl. Acad. Sci. USA, Vol. 90, pp. 10056-10060 (November 1993)
✓	Stryer et al., Biochemistry, Third edition, W.H. Freeman Company, New York, pages 31-33 (1998).

23552

PATENT TRADEMARK OFFICE

EXAMINER <i>J. N. S.</i>	DATE CONSIDERED <i>9/26/03</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

Date Mailed: June 10, 2005

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> <small>(Use several sheets if necessary)</small>	Docket Number: <b>11669.0139USC1</b>	Application Number: <b>10/692,299</b>
	Applicant: Ferraro et al.	
	Filing Date: <b>October 22, 2003</b>	Group Art Unit: <b>1644</b>

<b>23552</b> <small>PATENT TRADEMARK OFFICE</small>		
EXAMINER	DATE CONSIDERED	<u>9/26/05</u>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.		

\*Substitute Disclosure Statement Form (PTO-1449)

**Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE**

PAGE 4/4 \* RCVD AT 6/10/2005 4:17:03 PM (Eastern Daylight Time) \* SVR:USPTO-EFXRF-1/10 \* DNI:8729306 \* CSID:6123329081 \* DURATION (mm:ss):01:16

**Best Available Copy**